166 related articles for article (PubMed ID: 16051027)
1. BRCA1 in breast and ovarian cancer predisposition.
Billack B; Monteiro AN
Cancer Lett; 2005 Sep; 227(1):1-7. PubMed ID: 16051027
[TBL] [Abstract][Full Text] [Related]
2. Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition.
Mirkovic N; Marti-Renom MA; Weber BL; Sali A; Monteiro AN
Cancer Res; 2004 Jun; 64(11):3790-7. PubMed ID: 15172985
[TBL] [Abstract][Full Text] [Related]
3. The RAD51 135 G>C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers.
Jakubowska A; Gronwald J; Menkiszak J; Górski B; Huzarski T; Byrski T; Edler L; Lubiñski J; Scott RJ; Hamann U
Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):270-5. PubMed ID: 17301259
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer gene 1 (BRCA1): role in cell cycle regulation and DNA repair--perhaps through transcription.
Somasundaram K
J Cell Biochem; 2003 Apr; 88(6):1084-91. PubMed ID: 12647291
[TBL] [Abstract][Full Text] [Related]
5. The role of p53 mutation in BRCA1-associated ovarian cancer.
Rose SL; Buller RE
Minerva Ginecol; 2002 Jun; 54(3):201-9. PubMed ID: 12063435
[TBL] [Abstract][Full Text] [Related]
6. [BRCA1 and cancer: a new lead].
Larsen CJ
Bull Cancer; 2000 Oct; 87(10):693-4. PubMed ID: 11185523
[No Abstract] [Full Text] [Related]
7. BRCA1 gene in breast cancer.
Rosen EM; Fan S; Pestell RG; Goldberg ID
J Cell Physiol; 2003 Jul; 196(1):19-41. PubMed ID: 12767038
[TBL] [Abstract][Full Text] [Related]
8. Highlight: BRCA1 and BRCA2 proteins in breast cancer.
Daniel DC
Microsc Res Tech; 2002 Oct; 59(1):68-83. PubMed ID: 12242698
[TBL] [Abstract][Full Text] [Related]
9. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
10. Missense mutations of BRCA1 gene affect the binding with p53 both in vitro and in vivo.
Quaresima B; Faniello MC; Baudi F; Crugliano T; Di Sanzo M; Cuda G; Costanzo F; Venuta S
Oncol Rep; 2006 Oct; 16(4):811-5. PubMed ID: 16969499
[TBL] [Abstract][Full Text] [Related]
11. Evolution of the tumor suppressor BRCA1 locus in primates: implications for cancer predisposition.
Pavlicek A; Noskov VN; Kouprina N; Barrett JC; Jurka J; Larionov V
Hum Mol Genet; 2004 Nov; 13(22):2737-51. PubMed ID: 15385441
[TBL] [Abstract][Full Text] [Related]
12. [A paradox and three egnimas about the role of BRCA1 in breast and ovarian cancers].
Feunteun J
J Soc Biol; 2004; 198(2):123-6. PubMed ID: 15368961
[TBL] [Abstract][Full Text] [Related]
13. Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation.
DelloRusso C; Welcsh PL; Wang W; Garcia RL; King MC; Swisher EM
Mol Cancer Res; 2007 Jan; 5(1):35-45. PubMed ID: 17259345
[TBL] [Abstract][Full Text] [Related]
14. Glucose-regulated protein 78 as a novel effector of BRCA1 for inhibiting stress-induced apoptosis.
Yeung BH; Kwan BW; He QY; Lee AS; Liu J; Wong AS
Oncogene; 2008 Dec; 27(53):6782-9. PubMed ID: 18776923
[TBL] [Abstract][Full Text] [Related]
15. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
[TBL] [Abstract][Full Text] [Related]
16. G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history.
Anagnostopoulos T; Pertesi M; Konstantopoulou I; Armaou S; Kamakari S; Nasioulas G; Athanasiou A; Dobrovic A; Young MA; Goldgar D; Fountzilas G; Yannoukakos D
Breast Cancer Res Treat; 2008 Jul; 110(2):377-85. PubMed ID: 17902052
[TBL] [Abstract][Full Text] [Related]
17. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.
Egeli U; Cecener G; Tunca B; Tasdelen I
Cancer Invest; 2006; 24(5):484-91. PubMed ID: 16939956
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer susceptibility testing: past, present and future.
Goldberg JI; Borgen PI
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1205-14. PubMed ID: 16925486
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation of ATR-interacting protein on Ser239 mediates an interaction with breast-ovarian cancer susceptibility 1 and checkpoint function.
Venere M; Snyder A; Zgheib O; Halazonetis TD
Cancer Res; 2007 Jul; 67(13):6100-5. PubMed ID: 17616665
[TBL] [Abstract][Full Text] [Related]
20. Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.
King TA; Li W; Brogi E; Yee CJ; Gemignani ML; Olvera N; Levine DA; Norton L; Robson ME; Offit K; Borgen PI; Boyd J
Ann Surg Oncol; 2007 Sep; 14(9):2510-8. PubMed ID: 17597348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
